What is the best medication for treating post‑stroke headaches?

Post-Stroke Headaches: Treatment Recommendations

For post-stroke headaches, start with amitriptyline 75 mg at bedtime as first-line therapy, with lamotrigine as an alternative first-line option if amitriptyline is not tolerated or contraindicated. 1

Understanding Post-Stroke Headache

Post-stroke headache is common, affecting approximately 10-23% of stroke survivors beyond 3 months 2, 3, 4. These headaches typically present with tension-type features rather than severe migraine patterns, though migraine-like presentations occur in up to 58% of persistent cases 4. The condition significantly impacts quality of life and rehabilitation outcomes but remains undertreated 5, 2.

First-Line Pharmacotherapy

Primary Recommendation: Amitriptyline

• Dosing: 75 mg at bedtime
• Evidence: Demonstrated to lower daily pain ratings and improve global functioning in central post-stroke pain 1
• Mechanism: Addresses neuropathic pain component common in post-stroke headaches
• Caution: Monitor for anticholinergic effects, particularly in elderly patients; contraindicated in recent myocardial infarction

Alternative First-Line: Lamotrigine

• Evidence: Reduces daily pain ratings and cold-induced pain 1
• Limitation: Only 44% of patients achieve good clinical response
• Consideration: Use when amitriptyline is contraindicated or causes intolerable side effects

Second-Line Options

If first-line treatments fail or are not tolerated, consider these alternatives in order 1:

1. Pregabalin: Mixed evidence for pain reduction but improves sleep and anxiety
2. Gabapentin: Not well-studied specifically for post-stroke pain but effective in other neuropathic conditions
3. Carbamazepine or Phenytoin: Usefulness not well-established; reserve for refractory cases

Treatment Approach Based on Headache Pattern

For Tension-Type Features (Most Common)

• Start with amitriptyline 75 mg at bedtime
• If inadequate response after 4-6 weeks, add or switch to lamotrigine
• Consider acetaminophen 1000 mg for acute exacerbations 6, 7

For Migraine-Like Features

• Acute treatment: NSAIDs (ibuprofen 400-800 mg) or acetaminophen 1000 mg 6, 7
• Preventive: Amitriptyline remains first-line
• Critical caveat: Triptans require careful consideration in stroke patients due to vasoconstrictive properties—generally avoid unless cleared by neurology and patient is remote from stroke event 5, 2

Important Clinical Considerations

Medication Selection Factors

Individualize based on:

• Stroke type and timing (ischemic vs. hemorrhagic)
• Cardiovascular risk factors
• Concurrent medications (particularly anticoagulants/antiplatelets)
• Comorbid depression or sleep disturbance (favors amitriptyline)
• Seizure history (favors anticonvulsants)

Monitoring Strategy

Use standardized measures 1:

• Pain diaries
• Visual analog scales
• Headache impact questionnaires (e.g., HIT-6)
• Assess response every 4-6 weeks

Critical Pitfalls to Avoid

1. Medication Overuse Headache: Monitor frequency of acute medication use

   • NSAIDs: Limit to <15 days/month
   • Avoid opioids and butalbital entirely 8

2. Triptan Use: Exercise extreme caution

   • Contraindicated in patients with recent stroke, uncontrolled hypertension, or significant cardiovascular disease
   • No robust safety data in post-stroke population 5, 2
   • If considering, ensure patient is >6 months post-stroke with neurology clearance

3. CGRP Antagonists: Limited evidence for safety/efficacy in post-stroke patients 5—insufficient data to recommend

4. Opioids: Avoid due to dependency risk, rebound headaches, and lack of efficacy for chronic headache 8, 9

Adjunctive Strategies

Combine pharmacotherapy with 1:

• Interprofessional pain management (physical therapy, occupational therapy)
• Treatment of comorbid conditions (depression, sleep disorders, musculoskeletal issues)
• Addressing post-stroke fatigue, which correlates with headache persistence 3

When to Escalate Care

Consider neurology or pain specialist referral if:

• Inadequate response to two first-line agents
• Severe functional impairment despite treatment
• Concern for medication overuse headache
• Need for interventional procedures (motor cortex stimulation for intractable cases—reserved for extreme refractory situations) 1

Evidence Gaps

Current treatment recommendations are extrapolated primarily from central post-stroke pain studies rather than headache-specific trials 1. The 2016 AHA/ASA stroke rehabilitation guidelines provide the strongest evidence base, though specific post-stroke headache trials remain limited 5, 2. Treatment should prioritize harm reduction while awaiting more definitive efficacy data.